Form D · Other Health Care
Protibea Therapeutics, Inc.
Georgetown, TX · CIK 0001864104
Offering snapshot reported Aug 18, 2025 · SEC filing
- Reported sold
- $200K Offering amount: $11.7M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Jul 30, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 18, 2025 | Initial | $200,000 | No comparison | 2 | SEC filing |
| May 28, 2021 | Initial | $770,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-555107
Source: Form D, filed Aug 18, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Chamberlin | Director, Executive |
| Yu Ge | Director |
| Jim Moriarty | Director, Executive |
| Harry Oken | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
1108 Legacy Crossing
Georgetown, TX, 78628
Georgetown, TX, 78628